Chest mass - Large Biopsy 3-6 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Larger chest lesion biopsy.

₹666₹951

30% OFF

Chest Mass - Large Biopsy (3-6 cm)

Why is it done?
- Obtains tissue samples from chest masses measuring 3-6 cm for definitive diagnosis of pulmonary or mediastinal lesions
- Determines whether a mass is benign (non-cancerous) or malignant (cancerous) through histopathological examination
- Confirms suspected diagnoses such as lung cancer, lymphoma, infection, or other thoracic malignancies
- Provides tissue for immunohistochemistry, molecular testing, and genetic analysis to guide treatment planning
- Performed when imaging findings are indeterminate and clinical suspicion warrants tissue diagnosis
- Typically performed after initial imaging (CT or ultrasound) identifies a mass requiring further characterization
Normal Range
- This is a qualitative tissue biopsy test without numerical reference ranges
- Normal Result: Benign tissue with normal cellular architecture; no malignant cells identified; results may indicate granulomatous disease, infection, benign neoplasm, or inflammatory process
- Abnormal Result: Malignant cells present; specific tumor type identified (carcinoma, sarcoma, lymphoma, etc.); results include pathological diagnosis with staging and grading information
- Indeterminate/Inconclusive: Insufficient tissue, poor sample quality, or findings that require additional testing or repeat biopsy
- Units of Measurement: Histological evaluation reported descriptively with microscopic classification and immunohistochemical markers
Interpretation
- Benign Diagnoses Include:
  - Granulomatous inflammation (tuberculosis, histoplasmosis, sarcoidosis)
  - Hamartoma or lipoma (benign tumors)
  - Pneumonia or abscess
  - Chronic inflammatory conditions
- Malignant Diagnoses Include:
  - Non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma, large cell carcinoma)
  - Small cell lung cancer
  - Lymphoma (Hodgkin or non-Hodgkin)
  - Mesothelioma
  - Metastatic cancer from distant primary sites
- Factors Affecting Results:
  - Tissue quality and quantity obtained during biopsy procedure
  - Proper specimen handling, fixation, and preservation
  - Pathologist expertise and familiarity with thoracic pathology
  - Availability of special stains and immunohistochemical markers
  - Sampling of representative areas within the mass (central vs. peripheral tissue)
- Clinical Significance:
  - Provides definitive diagnosis essential for treatment planning and prognosis
  - Tumor grading and staging information influences surgical versus chemotherapy/radiation decisions
  - Molecular and genetic markers guide targeted therapy selection
  - Benign diagnosis may eliminate need for aggressive treatment and allow conservative management
Associated Organs
- Primary Organ Systems:
  - Respiratory system (lungs and bronchi)
  - Mediastinum (space between lungs containing heart, esophagus, major vessels)
  - Lymphatic system (mediastinal and hilar lymph nodes)
  - Pleura (lung lining)
- Conditions Associated with Abnormal Results:
  - Lung cancer (most common reason for chest mass biopsy)
  - Mediastinal lymphoma
  - Pulmonary infections (tuberculosis, fungal pneumonia, abscess)
  - Sarcoidosis (chronic granulomatous disease)
  - Metastatic disease to chest from distant sites
  - Pleural mesothelioma
- Potential Complications/Risks Associated with Abnormal Results:
  - Malignancy progression requiring urgent treatment initiation
  - Potential for disease dissemination with active infection (TB exposure)
  - Need for immunosuppressive therapy in granulomatous conditions
  - Potential involvement of heart or major vessels with mediastinal masses
Follow-up Tests
- Recommended Based on Benign Results:
  - Follow-up chest imaging (CT or X-ray) at 3-6 months to assess stability
  - Infectious disease consultation if tuberculosis or fungal infection identified
  - Pulmonology or rheumatology evaluation for sarcoidosis or inflammatory conditions
  - Serum markers or clinical monitoring depending on specific diagnosis
- Recommended Based on Malignant Results:
  - PET-CT scan for staging and detecting metastatic disease
  - Brain MRI to assess for cerebral metastases
  - Molecular genetic testing (EGFR, ALK, KRAS, PD-L1) for targeted therapy planning
  - Pulmonary function testing and cardiopulmonary assessment before treatment
  - Oncology consultation for surgery, chemotherapy, radiation, or immunotherapy planning
  - Tumor markers (CEA, NSE, CYFRA 21-1) for baseline assessment and monitoring
- Monitoring Frequency:
  - Benign lesions: Imaging follow-up in 3-6 months, then annually for 1-2 years
  - Malignant diagnoses: Baseline staging within 2-4 weeks followed by treatment initiation; surveillance intervals depend on treatment type and disease stage
  - Post-treatment imaging: Every 3 months for first year, then every 6 months for 2-3 years, then annually
- Related Complementary Tests:
  - Chest CT scan with contrast for better mass characterization and adjacent anatomy
  - Bronchoscopy if endobronchial lesion suspected
  - Sputum cytology or culture if infection suspected
  - Flow cytometry if lymphoma suspected
  - Echocardiogram if mass effect on cardiac structures noted
Fasting Required?
- Fasting: No fasting is required for this biopsy procedure
- Pre-Procedure Preparation:
  - Light breakfast or normal meals permitted up to 2-4 hours before procedure
  - Clear liquids (water, juice, coffee without milk) may be consumed up to 1 hour before biopsy
- Medications to Avoid/Adjust:
  - Anticoagulants (warfarin, apixaban, dabigatran): Hold 3-5 days before procedure; consult with physician
  - Antiplatelet agents (aspirin, clopidogrel): Discontinue 5-7 days before procedure
  - NSAIDs (ibuprofen, naproxen): Avoid 3-5 days before biopsy
  - Continue all other medications unless specifically instructed otherwise
- Additional Patient Preparation Instructions:
  - Arrange transportation to procedure as sedation may be administered
  - Wear comfortable, loose-fitting clothing that allows easy access to chest area
  - Obtain recent imaging studies (CT/ultrasound) to be available for procedure guidance
  - Inform physician of pregnancy, allergy to medications or contrast agents, and any bleeding disorders
  - Sign informed consent after discussing risks and benefits of procedure
  - Plan for post-procedure rest; do not return to strenuous activity for 24-48 hours

How our test process works!